HOME >> BIOLOGY >> NEWS
Charting the future in prostate cancer care: A call to action

LOS ANGELES, Sept. 9 -- This year, an estimated 230,000 men will be diagnosed with prostate cancer in the United States, and 30,000 are expected to die from the disease. Today, about two million men are battling prostate cancer, and over the next decade, about three million more will be compelled to join the war. The need for new therapies is great, and since 1993, The Prostate Cancer Foundation has played a pivotal role in supporting and funding R&D breakthroughs to defeat this disease.

The timing is becoming ever more critical. As the baby boomer men reach the target age for prostate cancer, beginning at age 50, this disease will become the cancer with the greatest increase in incidence, in addition to being the most common non-skin cancer in the U.S. In fact, over the next decade, the number of new prostate cancer cases in the U.S. is expected to increase by 50 percent to more than 300,000 new cases per year. Unfortunately, even today, prostate cancer treatment and research has lagged behind other areas, such as that of breast cancer, where there has been recent progress in integration among specialties and late-stage innovation of new therapeutics.

On September 22, 2004, the Prostate Cancer Foundation (PCF) will release its Report to the Nation on Prostate Cancer, authored by 24 leading prostate cancer experts. A distinguished panel will present the major findings of the Report and its authors' calls to action to address the urgent need to improve the management of prostate cancer and accelerate the development of better treatments and a cure. The PCF will also debut a public service announcement campaign "It's a TEAM Approach: Prostate Cancer Treatment, Education, Awareness and Management". The PSA features golf legend Arnold Palmer, a prostate cancer survivor, who encourages a multi-disciplinary team approach to this deadly disease, which affects one in six men in their lifetime.

Who: Panelists and Special Gues
'"/>

Contact: Justin Jackson
jjackson@burnsmc.com
212-213-0006
Burns McClellan
9-Sep-2004


Page: 1 2 3

Related biology news :

1. Lights, Camera ... Reaction: Charting The Biological Effects Of Light InBillionths Of A Second
2. New fruitfly model of diabetes has future implications for pancreatic cell transplantation
3. Sandia experiments may reduce possibility of future water wars
4. Will a reduction in military spending improve our environmental future?
5. The future of HIV therapeutics is brightening, according to Gladstone Institutes Director
6. Engineering endurance: The future of the Olympics?
7. The future of nanotechnology
8. Chemoradioimmunotherapy for advanced breast cancer: hope for the future?
9. Endometriosis: Could angiostatic therapy be the new treatment of the future?
10. Plants for the future: A European vision for plant biotechnology towards 2025
11. Plant pathologists to discuss the future of organic farming

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Charting the future prostate cancer care call action

(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... Dec. 9, 2014  Wake Forest Baptist Medical Center today ... its School of Medicine. Funding for this $50 million ... that will be publicly launched next summer. ... the former 60 series R.J. Reynolds Tobacco Company complex, ... will begin immediately with plans to be ready to ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/19/2014)... The empty capsules market is experiencing growth ... technological innovations in the empty capsules market. The ... growth of the empty capsules market. , Get ... of Report , The report will enrich both ... to gauge the pulse of the market which ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... Audacity, a leading California-based health and science ... Huntsworth Health Group, is proud to announce the addition ... role, Gonzales will serve as Senior Vice President of ... welcome a talent of Jamie’s caliber to the Audacity ... is a proven healthcare innovation leader and brand management ...
Breaking Biology Technology:Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
Cached News: